TD Asset Management
SPRY icon

TD Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

TD Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60,200
Closed -$862K – 1393
2024
Q3 		$862K Buy
+60,200
New +$716K ﹤0.01% 1217

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

TD Asset Management's SPRY Position: Q4 2024 in Review

TD Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 60,200 shares — an estimated $862K sold.

TD Asset Management first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $862K in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • TD Asset Management reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TD Asset Management sold 60,200 ARS Pharmaceuticals shares in Q4 2024, an estimated $862K.
  • TD Asset Management first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • TD Asset Management's ARS Pharmaceuticals position peaked at $862K in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.